Heron Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Unaudited quarterly filing for the three and nine months ended September 30, 2016. Heron is a biotechnology company developing medicines using its Biochronomer drug-delivery technology. The FDA approved SUSTOL, the company’s first commercial product, on August 9, 2016; commercial sales began in October 2016, after the reporting period. The pipeline included HTX-019 for chemotherapy-induced nausea and vomiting and HTX-011 for post-operative pain.
Financial condition and key metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $30.2 million, versus $14.2 million | $73.6 million, versus $44.9 million |
| General and administrative expense | $5.3 million, versus $4.1 million | $15.5 million, versus $11.8 million |
| Sales and marketing expense | $12.2 million, versus $4.1 million | $35.0 million, versus $9.1 million |
| Net loss | $48.5 million, or $1.24 per share, versus $22.7 million, or $0.63 per share | $125.2 million, or $3.34 per share, versus $66.3 million, or $2.07 per share |
| Cash used in operating activities | $36.1 million | $95.6 million, versus $55.4 million |
There was no product revenue during the period, and gross margin information was not applicable. Total operating expenses were $47.7 million for the third quarter and $124.1 million for the nine-month period. Accumulated deficit was $538.0 million at September 30, 2016.
Cash and cash equivalents were $45.6 million and short-term investments were $43.3 million at September 30, 2016, totaling approximately $88.9 million, compared with $131.2 million at December 31, 2015. Total assets were $98.8 million and stockholders’ equity was $17.9 million.
Debt included $50.0 million outstanding under an 8% two-year subordinated secured promissory note issued to Tang Capital Partners, LP in August 2016, plus $5.9 million principal of 6% secured convertible notes, carried at $2.7 million net of discount. The promissory note may provide an additional $50.0 million subject to achievement of a corporate milestone. Both financings are secured by liens on substantially all assets; the convertible notes may be prepaid at the holders’ option.
Material changes versus the prior comparable periods
- Net loss increased 114% in the third quarter and 89% for the nine-month period compared with 2015, driven by higher development, commercialization and personnel costs.
- Research and development spending increased primarily because of HTX-011 Phase 2 clinical and manufacturing costs, higher personnel costs, stock-based compensation and HTX-019 development costs. SUSTOL-related spending declined as its Phase 3 program was completed in 2015.
- Sales and marketing expense increased substantially as Heron hired and trained a sales force and prepared for the SUSTOL launch. Management expected these expenses to increase in 2017.
- Operating cash burn increased, while cash and short-term investments declined by approximately $42.3 million from year-end 2015 despite $50.0 million of promissory-note financing.
- Heron capitalized $2.0 million of SUSTOL pre-launch inventory following FDA approval.
- In September 2016, the board accepted the resignations of three executive officers. The company estimated $6.5 million of realignment-related costs, including $3.9 million of severance and $2.6 million of accelerated non-cash stock-option expense; $4.7 million had been expensed through September 30 and $3.1 million accrued.
Guidance, outlook, commentary and risks
Management did not provide quantified revenue, earnings or cash-flow guidance. The company expected continuing substantial losses and negative operating cash flows while commercializing SUSTOL, advancing HTX-011 and HTX-019, and pursuing regulatory approvals.
Heron reported positive Phase 2 findings for HTX-011. In Study 202B, the 400 mg formulation reduced 24-hour pain intensity by 29.5% versus placebo, reduced 96-hour opioid consumption by 22.4%, and increased the proportion of opioid-free patients through 96 hours to 24.1% versus 6.5%. In Study 208, HTX-011 showed substantial reductions in pain and opioid consumption versus placebo and bupivacaine solution. These early- and mid-stage results remain subject to confirmation in later studies.
Key risks include uncertain market acceptance, pricing and reimbursement for newly launched SUSTOL; competition from branded and generic antiemetic and pain products; regulatory and post-marketing requirements; clinical-trial failure or delays for HTX-011 and HTX-019; dependence on third-party manufacturers and single-source suppliers; product liability and intellectual-property disputes; and the company’s need for additional financing. Management stated that available capital may be insufficient to fund operations and development until material recurring revenue is generated.
On October 18, 2016, after quarter-end, Heron entered into a seven-year-and-four-and-one-half-month San Diego lease. Annual base rent rises from $1.3 million for the first 12 months to a prorated $1.6 million for the final four-and-one-half months, plus other charges; the security deposit was $0.1 million.
Important facts for investors to verify
- Initial SUSTOL sales, commercial uptake, pricing, reimbursement and gross-margin performance after the October 2016 launch.
- Cash runway relative to the company’s approximately $95.6 million nine-month operating cash burn and planned 2017 commercialization and development spending.
- Achievement of the corporate milestone required for the additional $50.0 million promissory-note draw.
- Terms, covenants and potential dilution associated with the secured convertible notes, including approximately 7.4 million underlying shares.
- Progress, regulatory path and confirmatory clinical results for HTX-011 and HTX-019.
- Actual costs and timing of the executive realignment, severance obligations and new San Diego facilities commitment.
- Manufacturing capacity, supply continuity, post-marketing obligations and competitive threats affecting SUSTOL.